

QIAGEN to advance AI-driven drug discovery with graph-based AI and curated bioinformatics knowledge with NVIDIA

- **Collaboration integrates NVIDIA accelerated computing and the NVIDIA BioNeMo platform with QIAGEN Digital Insights' curated biomedical knowledge bases**
- **Goal to advance how disease mechanisms, therapeutic targets and biomarkers are identified**
- **Graph-based AI approach designed to help researchers explore mechanisms, therapeutic targets and biomarkers with greater speed, context and confidence**
- **Initial pilot programs available to select pharmaceutical and biotechnology partners, with broader availability in future stages following validation**

Venlo, the Netherlands, and Redwood City, California, May 19, 2026 – QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced at the 2026 BIO-IT World Conference & Expo in Boston that the QIAGEN Digital Insights bioinformatics business and its curated knowledge bases and bioinformatics expertise will be integrating NVIDIA accelerated computing and the NVIDIA BioNeMo platform to help researchers use AI more effectively in drug discovery.

The integration is designed to help pharmaceutical and biotechnology researchers better understand disease biology, identify promising therapeutic targets and uncover biomarkers that can support faster and more effective development of new medicines.

Drug discovery depends on connecting large amounts of complex biological information, including genes, diseases, pathways, compounds and clinical evidence. For many research teams, the challenge is finding the most relevant connections amid increasing amounts of data to understand why they matter and assess whether an AI-generated insight is supported by credible biology.

QIAGEN and NVIDIA are working to address this challenge through graph-based AI. This approach applies retrieval and reasoning techniques over biomedical knowledge graphs, allowing researchers to explore evidence across biological systems and supporting a path toward agentic, multi-step workflows for drug discovery.

“QIAGEN Digital Insights has spent more than 25 years building the biomedical knowledge foundation that researchers rely on to interpret complex biology,” said Nitin Sood, Senior Vice President and Head of Product Portfolio & Innovation at QIAGEN. “Through this collaboration with NVIDIA, we can accelerate the impact of that knowledge by combining it with advanced AI to help customers improve critical steps in drug discovery, from target identification to biomarker research and hypothesis generation.”

The collaboration is designed to support practical applications across the drug discovery lifecycle, including target identification and validation, drug repurposing, biomarker discovery, pathway analysis and hypothesis generation from multi-omics data. By combining curated biomedical knowledge, graph-based AI and accelerated computing, QIAGEN aims to help research teams move from complex data to better-informed discovery decisions.

Initial pilot programs will be made available to select pharmaceutical and biotechnology partners, with broader availability of these new solutions expected following validation.

Media Release

QIAGEN Digital Insights is developing a range of new AI-enhanced solutions designed to help life sciences organizations extract more value from complex biological, clinical and molecular data.

These solutions build on more than 25 years of curated biomedical knowledge, including knowledge bases used by more than 150,000 scientists worldwide and supported by more than 70,000 scientific publications. By organizing evidence across genes, diseases, pathways, compounds, clinical insights and more than 30,000 diseases, QIAGEN Digital Insights provides the scientific context needed to help researchers assess whether AI-generated insights are biologically credible, novel and relevant to drug discovery.

QIAGEN's Discovery Platform integrates curated information across genes, diseases, pathways, compounds and clinical insights. To support AI-driven querying across this knowledge graph, the platform is designed to incorporate graph-based retrieval AI drawing on frameworks such as PyTorch Geometric and GPU accelerated GraphRAG systems, [with delivery through the NVIDIA BioNeMo platform](#). This will enable researchers to ask natural language questions across biomedical knowledge graphs while retaining a clear link to structured scientific evidence.

To learn more about the pilot program or explore how the QIAGEN Discovery Platform can support your drug discovery workflows, visit <https://digitalinsights.qiagen.com/qiagen-discovery-platform> or contact Matthew.Mansson@qiagen.com.

About QIAGEN

QIAGEN N.V., a Netherlands-based holding company, is a global leader in Sample to Insight solutions that enable customers to extract and analyze molecular information from biological samples containing the building blocks of life. Our Sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis, while bioinformatics support the interpretation of complex data to deliver actionable insights. Automation solutions integrate these steps into streamlined, cost-effective workflows. QIAGEN serves more than 500,000 customers worldwide in the Life Sciences (academia, pharmaceutical R&D and industrial applications such as forensics) and molecular diagnostics (clinical healthcare). As of March 31, 2026, QIAGEN employed approximately 5,500 people across more than 35 locations. For more information, visit www.qiagen.com.

Forward-Looking Statement

Certain statements contained in this press release may be considered forward-looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended and Section 21E of the U.S. Securities Exchange Act of 1934, as amended. These statements can be identified by the use of forward-looking terminology such as "believe", "hope", "plan", "intend", "seek", "may", "will", "could", "should", "would", "expect", "anticipate", "estimate", "continue", "target" or other similar words. To the extent that any of the statements contained herein relating to QIAGEN's products, timing for launch and development, marketing and/or regulatory approvals, financial and operational outlook, growth and expansion, acquisitions, collaborations, markets, strategy or operating results, including without limitation its expected net sales, net sales of particular products, net sales in particular geographies, adjusted net sales, expansion of adjusted operating income margin, returns to shareholders, progressive dividend payments, product portfolio management, product launches (including anticipated launches of our sequencing solutions, testing platforms, panels and systems), leveraging AI technology, improvements in operating and financial leverage, currency movements against the U.S. dollar, plans for investment in our portfolio and share repurchase commitments, our expectations relating to our adjusted tax rate, debt maturity and repayment, our ability to grow adjusted earnings per share at a greater rate than sales, our ability to improve operating efficiencies and maintain disciplined capital allocation, are forward-looking, such statements are based on current expectations and assumptions that involve a number of uncertainties and risks. Such uncertainties and risks include, but are not limited to, risks associated with our dependence on the development and success of new products; management of growth and expansion of operations (including the effects of currency fluctuations, tariffs, tax laws, regulatory processes and logistics and supply chain dependencies); variability of operating results; integration of

Media Release

acquired businesses; changes in relationships with customers, suppliers and strategic partners; competition; rapid or unexpected changes in technologies; fluctuations in demand for QIAGEN's products (including fluctuations due to general economic conditions, the level and timing of customers' funding, budgets and other factors, including delays or limits in the amount of reimbursement approvals or public health funding); our ability to obtain and maintain product regulatory approvals; difficulties in successfully adapting QIAGEN's products to integrated solutions and producing such products; the ability of QIAGEN to identify and develop new products and to differentiate and protect our products from competitors' products; market acceptance of new products and the integration of acquired technologies and businesses; actions of governments, global or regional economic developments, including inflation and changing interest rates, weather or transportation delays, natural disasters, cyber security breaches, political or public health crises and the resulting impact on the demand for our products and other aspects of our business, or other force majeure events; litigation risk, including patent litigation and product liability; debt service obligations; volatility in the public trading price of our common shares; as well as the possibility that expected benefits related to recent or pending acquisitions may not materialize as expected; and the other factors discussed under the heading "Risk Factors" in our most recent Annual Report on Form 20-F. For further information, please refer to the discussions in reports that QIAGEN has filed with, or furnished to, the U.S. Securities and Exchange Commission.

Contacts QIAGEN:

Public Relations

e-mail: pr@QIAGEN.com

Investor Relations

e-mail: ir@QIAGEN.com